Test Price
2,800 AED✅ Home Collection Available
TBC1D24 Gene (EIEE16) Next-Generation Sequencing DNA Test in UAE | 2800 AED
✅ 99.9% Diagnostic Sensitivity via ISO 15189 & ISO 9001:2015 Accredited Processing
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — Available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by DHA-licensed genetics specialists.
Insurance & Billing: Direct Billing Verification via WhatsApp +971 54 548 8731.
Executive Summary & Core Metrics
This highly accurate, single-gene DNA test targets pathogenic variants in TBC1D24, diagnosing Early Infantile Epileptic Encephalopathy Type 16 (EIEE16) — a severe neonatal-onset seizure disorder. By pinpointing the genetic etiology, families in the UAE gain a definitive diagnosis, guiding anti-epileptic therapy and accurate recurrence risk counseling. The test employs Next-Generation Sequencing (NGS) with Sanger confirmation, delivering results within 3–4 weeks at a cost of 2,800 AED inclusive of pre-test pedigree counseling and telephonic post-test clinical guidance from a DHA-licensed consultant.
Test Overview & Methodology
The TBC1D24 NGS test provides comprehensive coverage of all coding regions and intron-exon boundaries of the TBC1D24 gene. Variants are confirmed via Sanger sequencing to ensure 99.9% analytical sensitivity. This dedicated single-gene approach outperforms broad epilepsy panels by delivering deeper read depth, higher specificity for EIEE16, and a faster turnaround time for critical neonatal cases.
| Feature | Our Test — TBC1D24 NGS | Broad Epilepsy Gene Panel |
|---|---|---|
| Precision | 100% targeted coverage of TBC1D24 coding regions; deep sequencing (500x minimum) | Multi-gene coverage; may miss deep intronic or low-coverage TBC1D24 variants |
| Methodology | NGS with orthogonal Sanger confirmation of all pathogenic calls | NGS panel only; single-gene confirmation often not performed |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Clinical Focus | Dedicated EIEE16 diagnosis, prognosis, and recurrence risk | Generalized epilepsy risk screening |
| Genetic Counseling | Included — pre-test pedigree analysis and post-test telephonic session | Optional and billed separately |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I recognize the profound uncertainty families face when a neonate presents with unexplained seizures. The TBC1D24 NGS test provides molecular clarity that directly informs treatment decisions and recurrence risk. However, a negative result does not exclude epileptic encephalopathy — other genetic etiologies, structural brain anomalies, or metabolic disorders may be responsible. Genomic findings must always be integrated with electroencephalography (EEG), neuroimaging (MRI), and thorough clinical assessment under the supervision of a DHA-licensed neurologist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
⚠️ Medication Advisory
Do not discontinue prescribed anti-epileptic medications without consulting your treating physician. Abrupt withdrawal can provoke life-threatening status epilepticus. Always follow your neurologist’s guidance regarding medication adjustments.
Safety Box: Exclusion Criteria & Emergency Red Flags
- Exclusion — Unstable Emergency: Infants experiencing active seizures requiring emergency stabilization must not postpone emergency care for sample collection. Test only after clinical stability is confirmed.
- Exclusion — Venipuncture Hypersensitivity: Known hypersensitivity to venipuncture materials; discuss alternative collection via FTA dried blood spot card with the referring clinician.
- Emergency Red Flags: If the child develops a prolonged seizure lasting more than five minutes, difficulty breathing, or loss of consciousness, call 998 (UAE ambulance) immediately and inform the attending emergency team about the pending genetic test.
Patient FAQ & Clinical Guidance
1. What is the TBC1D24 gene test used for?
This test diagnoses Early Infantile Epileptic Encephalopathy Type 16 (EIEE16), a severe neonatal-onset epilepsy syndrome caused by pathogenic variants in the TBC1D24 gene. Identifying the genetic cause enables tailored anti-epileptic therapy, accurate recurrence risk counseling for family planning, and avoids unnecessary invasive investigations.
2. How is the sample collected and what is the cost in the UAE?
Sample collection is performed via a standard peripheral blood draw (2–5 mL in EDTA tube) or an FTA dried blood spot card for infants with difficult venous access. Our VIP Mobile Phlebotomy service is available daily from 8 AM to 11 PM across Dubai and major UAE cities. The total test price is 2,800 AED, inclusive of pre-test counseling, NGS analysis, Sanger confirmation, and a post-test telephonic guidance session.
3. When will I receive the results and what support is offered after testing?
Results are delivered within 3–4 weeks from sample receipt at the laboratory. Every report includes a telephonic post-test clinical guidance session with our DHA-registered Consultant Medical Genetics, who will explain the findings, discuss implications for the child and family, and coordinate further specialist referrals if needed.
4. Does a negative result completely rule out epilepsy in my child?
No. A negative TBC1D24 result reduces but does not eliminate the likelihood of genetic epilepsy. Other genes, chromosomal abnormalities, structural brain lesions, or metabolic disorders can produce similar clinical presentations. Genetic results must be interpreted alongside EEG findings, brain MRI, and the child’s full clinical history by a DHA-licensed pediatric neurologist or geneticist.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License No. 1143 and strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all genetic data handling, storage, and sharing. Clinical testing and patient consent protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. Health information security frameworks follow Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and never shared without the explicit written consent of the patient or their legal guardian.
Clinical & Logistical Metadata
| Test Name | TBC1D24 Gene (EIEE16) Next-Generation Sequencing DNA Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) or FTA dried blood spot card |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | G40.4 |
| LOINC Code | 21649-1 |
| DHA Facility License & Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians